[go: up one dir, main page]

KR830007070A - 라니티딘 염산염의 제조방법 - Google Patents

라니티딘 염산염의 제조방법 Download PDF

Info

Publication number
KR830007070A
KR830007070A KR1019810003689A KR810003689A KR830007070A KR 830007070 A KR830007070 A KR 830007070A KR 1019810003689 A KR1019810003689 A KR 1019810003689A KR 810003689 A KR810003689 A KR 810003689A KR 830007070 A KR830007070 A KR 830007070A
Authority
KR
South Korea
Prior art keywords
form2
ranitidine hydrochloride
ranitidine
hydrochloride
solvent
Prior art date
Application number
KR1019810003689A
Other languages
English (en)
Other versions
KR870001431B1 (ko
Inventor
레스리 크록키스 데렉
Original Assignee
배리 안토니 뉴삼
크랙소 그룹 리밋티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10516407&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR830007070(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 배리 안토니 뉴삼, 크랙소 그룹 리밋티드 filed Critical 배리 안토니 뉴삼
Publication of KR830007070A publication Critical patent/KR830007070A/ko
Application granted granted Critical
Publication of KR870001431B1 publication Critical patent/KR870001431B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)

Abstract

내용 없음

Description

라니티딘 염산염의 제조방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
FORM2 라니티딘 염산염을 적외선 스펙트럼한 결과로써 세로좌표는 투광도(%)로 , 가로좌표는 파수(cm-1)로 나타낸 그래프이다.

Claims (10)

  1. Form2 라니티딘 염산염을 제조하는 방법에 있어서, Form2 라니티딘 염산염을 전고체(null)로 광물성 기름을 사용하여 적외선 스텍트럼한 결과(표 1)의 주 피이크(main peak)들이 나타나고, 직경이 114.6 mm인 카메라를 사용하여 데바이 세러법에 의해서 CoKa방사선에 12시간, CuKa방사선에 3시간 동안 노출시키므로써 "d"중심거리 및 상대적 세기(I)(s=강함, m∥중간, w=약함, v=매우, d=확산)로 표현할 수 있는 다음 X선 분말회절선(표 2)을 얻을 수 있으며, 여러가지 조건 하에서 용매를 함유하는 용액으로부터 라니티딘 염산염을 결정화하여 Form2 라니티딘 염산염을 산출함을 특징으로 하는 Form2 라니티딘 염산염의 제조방법.
  2. 청구범위 1항에 있어서, Form2 라니티딘 염산염을 염산과 반응시키므로써 라니티딘 유리 염기로부터 제조됨을 특징으로 하는 Form2 라니티딘 염산염의 제조방법.
  3. 청구범위 2항에 있어서, 히드록실성 용매 중에서 실시됨을 특징으로 하는 Form2 라니티딘 염산염의 제조방법.
  4. 청구범위 3항에 있어서, 프로판-2-올에 라니티딘을 함유하고 있는 용액을 섭씨 최고 70도 까지의 온도에서 염산으로 처리하고, 그 아음에 프로판-2-올을 더 첨가하여 Form2 라니티딘 염산염을 결정화시킴을 특징으로 하는 Form2 라니티딘 염산염의 제조방법.
  5. 청구범위 3항에 있어서, 2-메틸프로판-2-올, 부탄-2-올, 혹은 에탄올에 라니티딘을 함유하고 있는 용액을 섭씨 온도 최고 70도 까지의 온도에서 염산으로 처리하여 Form2 라니티딘 염산염을 결정화시킴을 특징으로 하는 Form2 라니티딘 염산염의 제조방법.
  6. 청구범위 4항이나 5항에 있어서, 개시 용액은 최고 7% v/v의 물을 함유함을 2 특징으로 하는 Form2 라니티딘 염산염의 제조방법.
  7. 청구범위 1항에 있어서 Form2 라니티딘 염산염은 라니티딘 염산염을 재결정화하므로써 제조됨을 특징으로 하는 Form2 라니티딘 염산염의 제조방법.
  8. 청구범위 7항에 있어서 재결정화하는 히드록실성 용매를 사용하므로써 일어남을 특징으로 하는 Form2 라니티딘 염산염의 제조방법.
  9. 청구범위 7항에 있어서, 용매는 프로판-2-올, 메탄올 혹은 에탄올임을 특징으로 하는 Form2 라니티딘 염산염의 제조방법.
  10. 청구범위 8항이나 9항에 있어서, 혼합할 수 있는 항-용매를 이 용액에 첨가하여 결정화를 완료시킴을 특징으로 하는 Form2 라니티딘 염산염의 제조방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019810003689A 1980-10-01 1981-10-01 라니티딘 염산염의 제조방법 KR870001431B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB8031634 1980-10-01
GB80/31634 1980-10-01

Publications (2)

Publication Number Publication Date
KR830007070A true KR830007070A (ko) 1983-10-14
KR870001431B1 KR870001431B1 (ko) 1987-08-06

Family

ID=10516407

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019810003689A KR870001431B1 (ko) 1980-10-01 1981-10-01 라니티딘 염산염의 제조방법

Country Status (29)

Country Link
US (2) US4521431A (ko)
JP (1) JPS5791983A (ko)
KR (1) KR870001431B1 (ko)
AT (1) AT389696B (ko)
AU (1) AU549119B2 (ko)
BE (1) BE890574A (ko)
CA (1) CA1202638A (ko)
CH (1) CH652122A5 (ko)
CZ (1) CZ280885B6 (ko)
DE (1) DE3139134A1 (ko)
DK (2) DK167794B1 (ko)
ES (1) ES8301954A1 (ko)
FR (1) FR2491067A1 (ko)
GR (1) GR72499B (ko)
HK (1) HK97985A (ko)
IE (1) IE51604B1 (ko)
IL (1) IL63968A (ko)
IT (1) IT1143237B (ko)
KE (1) KE3549A (ko)
LU (1) LU83661A1 (ko)
MY (1) MY8500747A (ko)
NL (1) NL8104482A (ko)
NZ (1) NZ198522A (ko)
PH (2) PH19489A (ko)
PT (1) PT73744B (ko)
SE (1) SE453500B (ko)
SK (1) SK277922B6 (ko)
ZA (1) ZA816809B (ko)
ZW (1) ZW24481A1 (ko)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK162525C (da) * 1983-07-15 1992-03-30 Richter Gedeon Vegyeszet Fremgangsmaade til fremstilling af ranitidin-hydroklorid
GB8629781D0 (en) * 1986-12-12 1987-01-21 Glaxo Group Ltd Pharmaceutical compositions
SE8704436D0 (sv) * 1987-11-13 1987-11-13 Pm Konsult Handelsbolag Anvendning av antisekretoriska substanser for nya indikationer
IL90245A (en) * 1988-05-11 1994-04-12 Glaxo Group Ltd Resin adsorbate comprising ranitidine together with a synthetic cation exchange resin, its preparation and pharmaceutical compositions containing it
GB8904182D0 (en) * 1989-02-23 1989-04-05 Glaxo Canada Pharmaceutical compositions
US5169864A (en) * 1991-11-15 1992-12-08 Baxter International Inc. Unbuffered premixed ranitidine formulation
CN1048984C (zh) * 1991-12-20 2000-02-02 多坎化学有限公司 晶形1呋喃硝胺氢氯化物的制备
US5338871A (en) * 1991-12-20 1994-08-16 Torcan Chemical Ltd. Preparation of form 1 ranitidine hydrochloride
CN1055090C (zh) * 1993-03-12 2000-08-02 法玛西雅厄普约翰美国公司 结晶性头孢噻夫游离酸
DE4341310A1 (de) * 1993-12-03 1995-06-08 Hexal Pharma Gmbh Tablette oder Kapsel mit einem Gehalt an stabilem Ranitidinhydrochlorid Form 1
US5407687A (en) * 1994-02-22 1995-04-18 Glaxo Inc. Ranitidine solid dosage form
CA2120874E (en) * 1994-04-08 2002-01-08 Keshava Murthy Form of form 1 ranitidine
EP0754182A1 (en) * 1994-04-08 1997-01-22 Brantford Chemicals Inc. Form 1 ranitidine hydrochloride with increased density
HU226827B1 (en) 1994-04-15 2009-11-30 Upjohn Co Novel crystal forms of 1-[5-methanesulfonamidoindolyl-2-carbonyl]-4-[3-(1-methylethylamino)-2-piridinyl]piperazine
IN181698B (ko) * 1994-05-13 1998-09-05 Ranbaxy Lab Ltd
IN181699B (ko) * 1994-05-13 1998-09-05 Ranbaxy Lab Ltd
NZ272054A (en) * 1994-05-13 1996-05-28 Ranbaxy Lab Ltd Process for producing form 1 ranitidine hydrochloride
US20030045722A1 (en) * 1994-05-18 2003-03-06 Henton Daniel R. Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof
EP1178041A1 (en) * 1994-05-18 2002-02-06 Aventis Pharmaceuticals Inc. Process for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives
EP0694540B1 (en) 1994-06-24 1998-08-19 Ranbaxy Laboratories Limited Process for the manufacture of form 1 ranitidine hydrochloride
CA2201735A1 (en) * 1994-11-18 1996-05-30 The Upjohn Company A new physically stable solid form of a fluoroquinolone
US5538737A (en) * 1994-11-30 1996-07-23 Applied Analytical Industries, Inc. Oral compositions of H2 -antagonists
US5663381A (en) * 1995-04-21 1997-09-02 Hexal Pharmaceuticals, Inc. Process for preparing form 1 ranitidine hydrochloride
US5686588A (en) * 1995-08-16 1997-11-11 Yoo; Seo Hong Amine acid salt compounds and process for the production thereof
WO1997035853A1 (en) * 1996-03-25 1997-10-02 Hoechst Marion Roussel, Inc. Process for the preparation of form 1 ranitidine hydrochloride
DK0903345T3 (da) 1997-08-08 2000-10-23 Aventis Pharma Gmbh Krystalform af N-(4-trifluormethylphenyl)-5-methyl-isoxazol-4-carboxamid
US6287693B1 (en) 1998-02-25 2001-09-11 John Claude Savoir Stable shaped particles of crystalline organic compounds
IT1317858B1 (it) 2000-02-29 2003-07-15 Pharmexcel S R L Allomorfo del cloridrato dell'isomero z di derivato dialchilamminofurano, procedimento per la sua produzione e composizione
GB2357762B (en) * 2000-03-13 2002-01-30 Lundbeck & Co As H Crystalline base of citalopram
US20020183553A1 (en) * 2000-10-19 2002-12-05 Ben-Zion Dolitzky Crystalline venlafaxine base and novel polymorphs of venlafaxine hydrochloride, processes for preparing thereof
US20060173064A1 (en) * 2001-08-24 2006-08-03 Lippa Arnold S (-)-1-(3,4-Dichlorophenyl)-3-azabi cyclo[3.1.0]hexane, compositions thereof, and uses for treating alcohol-related disorders
US6569887B2 (en) * 2001-08-24 2003-05-27 Dov Pharmaceuticals Inc. (−)-1-(3,4-Dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake
US7235655B2 (en) * 2002-03-22 2007-06-26 Pharmacia & Upjohn Company Processes to prepare eplerenone
AR040661A1 (es) * 2002-07-26 2005-04-13 Theravance Inc Diclorhidrato cristalino de n-{2-[-((r)-2-hidroxi-2-feniletilamino)fenil]etil}-(r)-2hidroxi-2-(3-formamido-4-hidroxifenil)etilamina, agonista del receptor adrenergico beta 2
US20080081834A1 (en) 2002-07-31 2008-04-03 Lippa Arnold S Methods and compositions employing bicifadine for treating disability or functional impairment associated with acute pain, chronic pain, or neuropathic disorders
US7166641B2 (en) * 2002-10-02 2007-01-23 Yung Shin Pharmaceutical Industrial Co., Ltd. Pharmaceutically acceptable salts containing local anesthetic and anti-inflammatory activities and methods for preparing the same
AU2003286889A1 (en) * 2002-11-08 2004-06-03 Dov Pharmaceutical, Inc. Polymorphs of bicifadine hydrochloride
TW200510277A (en) * 2003-05-27 2005-03-16 Theravance Inc Crystalline form of β2-adrenergic receptor agonist
US7384557B2 (en) * 2003-07-14 2008-06-10 Applied Ambient Extraction Process Consultants, Llc Method and apparatus for removing solute from a solid solute-bearing product
TWI328006B (en) * 2003-12-26 2010-08-01 Nissan Chemical Ind Ltd Crystal form of quinoline compound and process for its production
US20070043100A1 (en) 2005-08-16 2007-02-22 Hagen Eric J Novel polymorphs of azabicyclohexane
US20060100263A1 (en) * 2004-11-05 2006-05-11 Anthony Basile Antipyretic compositions and methods
US20060100271A1 (en) * 2004-11-08 2006-05-11 Keith Whitehead Stabilized aqueous ranitidine compositions
EP2719384B1 (en) 2005-07-27 2018-08-08 Otsuka America Pharmaceutical, Inc. Novel 1-naphthyl-3-azabicyclo[3.1.0]hexanes:preparation and use to treat neuropsychiatric disorders
DE102005035891A1 (de) * 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
US20080045725A1 (en) 2006-04-28 2008-02-21 Murry Jerry A Process For The Synthesis of (+) And (-)-1-(3,4-Dichlorophenyl)-3-Azabicyclo[3.1.0]Hexane
AU2007309534B2 (en) * 2006-10-20 2012-08-16 Scinopharm Singapore Pte, Ltd. Process for making crystalline anhydrous docetaxel
US8138377B2 (en) 2006-11-07 2012-03-20 Dov Pharmaceutical, Inc. Arylbicyclo[3.1.0]hexylamines and methods and compositions for their preparation and use
US20090069374A1 (en) * 2007-06-06 2009-03-12 Phil Skolnick Novel 1-Heteroaryl-3-Azabicyclo[3.1.0]Hexanes, Methods For Their Preparation And Their Use As Medicaments
US9133159B2 (en) 2007-06-06 2015-09-15 Neurovance, Inc. 1-heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments
TW201011043A (en) * 2008-06-20 2010-03-16 Chugai Pharmaceutical Co Ltd Crystal of spiroketal derivatives and process for preparation of spiroketal derivatives
US9006434B2 (en) 2011-06-30 2015-04-14 Toray Industries, Inc. Crystals of glycine derivative and pharmaceutical use thereof
US20140206740A1 (en) 2011-07-30 2014-07-24 Neurovance, Inc. Use Of (1R,5S)-(+)-(Napthalen-2-yl)-3-Azabicyclo[3.1.0]Hexane In The Treatment Of Conditions Affected By Monoamine Neurotransmitters
CN106432147B (zh) * 2015-05-26 2018-04-17 烟台市华文欣欣医药科技有限公司 一种制备治疗胃病的药物盐酸雷尼替丁化合物的方法
CN105030694A (zh) * 2015-08-04 2015-11-11 青岛蓝盛洋医药生物科技有限责任公司 一种治疗胃溃疡的药物盐酸雷尼替丁组合物干混悬剂
CN104971053A (zh) * 2015-08-05 2015-10-14 青岛蓝盛洋医药生物科技有限责任公司 一种治疗消化系统疾病的药物盐酸雷尼替丁组合物片剂
CN105055331A (zh) * 2015-08-31 2015-11-18 青岛蓝盛洋医药生物科技有限责任公司 一种治疗消化性溃疡的药物盐酸雷尼替丁组合物颗粒剂
WO2021079183A1 (en) * 2019-10-21 2021-04-29 Sms Pharmaceuticals Limited Isopropyl alcohol solvent free crystalline ranitidine hydrochloride form-2 which is free of nitrosamine (ndma) impurity

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1565966A (en) * 1976-08-04 1980-04-23 Allen & Hanburys Ltd Aminoalkyl furan derivatives
US4233302A (en) * 1977-12-23 1980-11-11 Glaxo Group Limited Amine derivatives and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
DK167923B1 (da) 1994-01-03
CZ403591A3 (en) 1994-01-19
IE51604B1 (en) 1987-01-21
LU83661A1 (fr) 1983-06-08
KR870001431B1 (ko) 1987-08-06
AU7595581A (en) 1982-04-08
IE812287L (en) 1982-04-01
HK97985A (en) 1985-12-13
CH652122A5 (fr) 1985-10-31
FR2491067B1 (ko) 1984-09-07
FR2491067A1 (fr) 1982-04-02
IL63968A0 (en) 1981-12-31
PH19489A (en) 1986-05-14
DE3139134C2 (ko) 1990-04-19
PH21761A (en) 1988-02-18
ZW24481A1 (en) 1983-04-27
ZA816809B (en) 1983-05-25
CA1202638A (en) 1986-04-01
US4521431A (en) 1985-06-04
US4672133A (en) 1987-06-09
AU549119B2 (en) 1986-01-16
SE8105812L (sv) 1982-04-02
PT73744B (en) 1983-10-31
NL8104482A (nl) 1982-05-03
PT73744A (en) 1981-10-01
IT1143237B (it) 1986-10-22
JPH0443070B2 (ko) 1992-07-15
DK436281A (da) 1982-04-02
GR72499B (ko) 1983-11-15
DK33792A (da) 1992-03-12
SK403591A3 (en) 1995-08-09
KE3549A (en) 1985-08-16
MY8500747A (en) 1985-12-31
DE3139134A1 (de) 1982-05-19
CZ280885B6 (cs) 1996-04-17
IT8149407A0 (it) 1981-10-01
IL63968A (en) 1985-10-31
ES505951A0 (es) 1983-01-01
SK277922B6 (en) 1995-08-09
DK167794B1 (da) 1993-12-13
SE453500B (sv) 1988-02-08
NZ198522A (en) 1985-07-12
DK33792D0 (da) 1992-03-12
BE890574A (fr) 1982-04-01
ATA422281A (de) 1989-06-15
AT389696B (de) 1990-01-10
JPS5791983A (en) 1982-06-08
ES8301954A1 (es) 1983-01-01

Similar Documents

Publication Publication Date Title
KR830007070A (ko) 라니티딘 염산염의 제조방법
FR2313338A1 (fr) Procede pour preparer des ethers
KR880013916A (ko) β-D-페닐티옥실로사이드류의 제조방법
KR860008200A (ko) 신규한 4'-탈메틸-4-에피포도필로톡신 유도체의 제조방법
KR890009583A (ko) 구리 필름 발포체의 제조방법
KR840001968A (ko) 4-페닐퀴나졸린 유도체의 제조방법
KR870011168A (ko) 폴리에테르 수지의 제조 방법
ES427548A1 (es) Procedimiento para la preparacion de 2,2,6,6-tetrametil-4- oxopiperidina.
KR840008338A (ko) 1,2,4-트리아졸-3-카르복시아미드류의 제조방법
KR950011401A (ko) 아세토아세트 아릴아미드의 제조방법
SU489326A3 (ru) Способ получени замещенных 2-ариламиноимидазолинов-(2)
KR830009077A (ko) 푸란 유도체의 제조방법
KR830002774A (ko) 7-아미노-데스아세톡시 세파로스포란산 유도체의 제조방법
SU582250A1 (ru) Способ получени -бис-(2,2,6,6-тетраметилпиперидил-4)оксамида
KR840002340A (ko) 1-(3-벤질옥시페닐)-1,1-디메틸헵탄 및 관련 중간체의 제조방법
KR830007614A (ko) 푸란유도체의 제조방법
KR860004064A (ko) 결정성 아미노메틸 화합물의 제조방법
SU1721049A1 (ru) Способ получени диметилсульфоксида-Д @
KR920014762A (ko) 디알킬아미노프로판디올의 제조방법
KR840009105A (ko) 1,4-디하이드로피리딘 유도체의 제조방법
SU405916A1 (ru) Способ получения алифатических эпоксидных смол
JPS51113882A (en) Method for preparing 1-(alpha -alkoxyalkyl)-uracil derivatives
SU586167A1 (ru) Способ получени алкилсульфоксидов
SU785292A1 (ru) Способ получени 1-метокси-1бутен-3-ина
KR910016673A (ko) 히드록시페닐프로피오네이트의 제조방법

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 19810930

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 19850809

Comment text: Request for Examination of Application

Patent event code: PA02011R01I

Patent event date: 19810930

Comment text: Patent Application

G160 Decision to publish patent application
PG1605 Publication of application before grant of patent

Comment text: Decision on Publication of Application

Patent event code: PG16051S01I

Patent event date: 19870707

O035 Opposition [patent]: request for opposition
PO0301 Opposition

Comment text: Request for Opposition

Patent event code: PO03011R01D

Patent event date: 19871002

O122 Withdrawal of opposition [patent]
PO1201 Withdrawal of opposition

Patent event date: 19871218

Patent event code: PO12011R01D

Comment text: Withdrawal of Opposition

E701 Decision to grant or registration of patent right
O073 Decision to grant registration after opposition [patent]: decision to grant registration
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 19880111

PO0701 Decision to grant registration after opposition

Comment text: Decision to Grant Registration

Patent event code: PO07011S01D

Patent event date: 19880111

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 19880215

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 19880215

End annual number: 3

Start annual number: 1

PR1001 Payment of annual fee

Payment date: 19900727

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 19910729

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 19920716

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 19930730

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee

Payment date: 19940802

Start annual number: 8

End annual number: 8

PR1001 Payment of annual fee

Payment date: 19950804

Start annual number: 9

End annual number: 9

PR1001 Payment of annual fee

Payment date: 19960719

Start annual number: 10

End annual number: 10

PR1001 Payment of annual fee

Payment date: 19970729

Start annual number: 11

End annual number: 11

PR1001 Payment of annual fee

Payment date: 19970830

Start annual number: 12

End annual number: 12

PR1001 Payment of annual fee

Payment date: 19990721

Start annual number: 13

End annual number: 13

PR1001 Payment of annual fee

Payment date: 20000726

Start annual number: 14

End annual number: 14

FPAY Annual fee payment

Payment date: 20010801

Year of fee payment: 15

PR1001 Payment of annual fee

Payment date: 20010801

Start annual number: 15

End annual number: 15

EXPY Expiration of term
PC1801 Expiration of term

Termination date: 20020611

Termination category: Expiration of duration